Pharmacokinetic and pharmacodynamic characterization of gliclazide in healthy volunteers

被引:16
|
作者
Kim, H [1 ]
Yun, M [1 ]
Kwon, KI [1 ]
机构
[1] Chungnam Natl Univ, Coll Pharm, Taejon 305764, South Korea
关键词
gliclazide; pharmacokinetics; pharmacodynamics; human;
D O I
10.1007/BF02976882
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Pharmacokinetic and pharmacodynamic properties of gliclazide were studied after an oral administration of gliclazide tablets in healthy volunteers. After an overnight fasting, gliclazide tablet was orally administered to 11 volunteers; Additional 10 volunteers were used as a control group (i.e., no gliclazide administration). Blood samples were collected, and the concentration determined for gliclazide and glucose up to 24 after the administration. Standard pharmacokinetic analysis was carried out for gliclazide. Pharmacodynamic activity of the drug was expressed by increase of glucose concentration (APG), by area under the increase of glucose concentration-time curve (AUC(DeltaPG)) or by the difference in increase of glucose concentration (DAPG) at each time between groups with and without gliclazide administration. Pharmacokinetic analysis revealed that C-max, T-max, CL/F (apparent clearance), V/F (apparent volume of distribution) and half-life of gliclazide were 4.69+/-1.38 mg/L, 3.45+/-1.11 h, 1.26+/-0.35 L/h, 17.78+/-5.27 L, and 9.99+/-2.15 h, respectively. When compared with the no drug administration group, gliclazide decreased significantly the AUC(DeltaPG) s at 1, 1.5, 2, 2.5, 3 and 4 h (p<0.05). The DeltaPGs were positively correlated with AUC(glidazide) at 1 and 1.5 h (p<0.05), and the correlation coefficient was maximum at 1 h (r = 0.642) and gradually decreased at 4 h after the administration. The AUC(DeltaPG)S were positively correlated with AUC(gliclazide) at 1, 2, 3 and 4 h (p<0.05), and the maximum correlation coefficient was obtained at 2 h (r=0.642) after the administration. The D-DeltaPG reached the maximum at 1 h, remained constant from 1 h to 3 h, and decreased afterwards. Therefore, these observations indicated that maximum hypoglycemic effect of gliclazide was reached at approximately at 1.5 h after the administration and the effect decreased, probably because of the homeostasis mechanism, in health volunteers.
引用
收藏
页码:564 / 568
页数:5
相关论文
共 50 条
  • [31] Pharmacokinetic and Pharmacodynamic Interaction of Nadolol With Itraconazole, Rifampicin and Grapefruit Juice in Healthy Volunteers
    Misaka, Shingen
    Miyazaki, Nozomu
    Yatabe, Midori S.
    Ono, Tomoyuki
    Shikama, Yayoi
    Fukushima, Tetsuhito
    Kimura, Junko
    JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (07) : 738 - 745
  • [32] A pharmacokinetic and pharmacodynamic study, in healthy volunteers, of a rapidly absorbed intranasal midazolam formulation
    Wermeling, Daniel P.
    Record, Kenneth A.
    Archer, Sanford M.
    Rudy, Anita C.
    EPILEPSY RESEARCH, 2009, 83 (2-3) : 124 - 132
  • [33] Population Pharmacokinetic/Pharmacodynamic Modeling of the Effect of Abrocitinib on QT Intervals in Healthy Volunteers
    Wang, Xiaoxing
    Gupta, Pankaj
    Malhotra, Bimal K.
    Farooqui, Saleem Ashley
    Le, Vu H.
    Wojciechowski, Jessica
    Mukherjee, Arnab
    Nicholas, Timothy
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (09): : 1036 - 1045
  • [34] Pharmacokinetic/Pharmacodynamic Modeling of Glucose Clamp Effects of Inhaled and Subcutaneous Insulin in Healthy Volunteers and Diabetic Patients
    Landersdorfer, Cornelia B.
    Jusko, William J.
    DRUG METABOLISM AND PHARMACOKINETICS, 2010, 25 (05) : 418 - 429
  • [35] Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers
    Cawello, Willi
    Rosenkranz, Bernd
    Schmid, Bernhard
    Wierich, Werner
    EPILEPSIA, 2013, 54 (03) : 530 - 536
  • [36] Pharmacokinetic/Pharmacodynamic Model of CW002, an Investigational Intermediate Neuromuscular Blocking Agent, in Healthy Volunteers
    Kaullen, Josh D.
    Owen, Joel S.
    Brouwer, Kim L. R.
    Heerdt, Paul M.
    Lien, Cynthia A.
    Savarese, John J.
    Schmith, Virginia D.
    ANESTHESIOLOGY, 2018, 128 (06) : 1107 - 1116
  • [37] Population Pharmacokinetic/Pharmacodynamic and Exposure-Response Modeling of Garadacimab in Healthy Volunteers and Patients With Hereditary Angioedema
    Garcia, Ramon
    Cheng, Shen
    Glassman, Fiona
    Sharma, Ankur
    De Miguel-Lillo, Bernardo
    Wiens, Matthew
    Johnston, Curtis
    Lawo, John-Philip
    Pragst, Ingo
    French, Jonathan
    Polhamus, Dan
    Nandy, Partha
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2025,
  • [38] Comparing the Efficacy of Various Insulin Types: Pharmacokinetic and Pharmacodynamic Modeling of Glucose Clamp Effects in Healthy Volunteers
    Chang, Yi Chien
    Jusko, William J.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2025,
  • [39] Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers
    Idrian García-García
    Ignacio Hernández-González
    Alina Díaz-Machado
    Carlos A. González-Delgado
    Sonia Pérez-Rodríguez
    Yanelda García-Vega
    Rosario Campos-Mojena
    Ángela D. Tuero-Iglesias
    Carmen M. Valenzuela-Silva
    Alieski Cruz-Ramírez
    Alis Martín-Trujillo
    Héctor Santana-Milián
    Pedro A. López-Saura
    Iraldo Bello-Rivero
    BMC Pharmacology and Toxicology, 17
  • [40] Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers
    Garcia-Garcia, Idrian
    Hernandez-Gonzalez, Ignacio
    Diaz-Machado, Alina
    Gonzalez-Delgado, Carlos A.
    Perez-Rodriguez, Sonia
    Garcia-Vega, Yanelda
    Campos-Mojena, Rosario
    Tuero-Iglesias, Angela D.
    Valenzuela-Silva, Carmen M.
    Cruz-Ramirez, Alieski
    Martin-Trujillo, Alis
    Santana-Milian, Hector
    Lopez-Saura, Pedro A.
    Bello-Rivero, Iraldo
    BMC PHARMACOLOGY & TOXICOLOGY, 2016, 17